In the bioequivalence studies , subjects first received one polyethylene oxide - or hypromellose-based tapentadol ER tablet ( 50 , 100 , 150 , 200 , or 250 mg ; one dose per study ) , then ( after washout ) the other formulation ( matching dose ) .